Naratuximab emtansine is under clinical development by Debiopharm International and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase II drugs for Follicular Lymphoma have a 45% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Naratuximab emtansine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Naratuximab emtansine overview
Naratuximab emtansine is under development for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma such as follicular lymphoma (FL), marginal zone lymphoma (MZL) /mucosa-associated lymphoid tissue (MALT), diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). It is administered intravenously. The drug candidate is based on Targeted Antibody Payload (TAP) technology. It was also under development for the treatment of chronic lymphocytic leukemia (CLL).
Debiopharm International overview
Debiopharm International, a subsidiary of Debiopharm Group, focuses on the development and manufacture of drugs for oncology and bacterial infections. The company offers oxaliplatin and triptorelin drugs. It is investigating proteins, peptides and small molecules to treat cancers, solid tumors, bone and joint infections and gastrointestinal disorders. Debiopharm is headquartered in Lausanne, Switzerland.
For a complete picture of Naratuximab emtansine’s drug-specific PTSR and LoA scores, buy the report here.